Close Menu

NEW YORK – Indivumed said today that it is partnering with Greek machine learning and analytics startup Gnosis Data Analysis to add artificial intelligence to its IndivuType multi-omics cancer research platform.

Hamburg, Germany-based Indivumed's IndivuType combines genomic, transcriptomic, proteomic, immuno-phenotype, and digital histopathology data with clinical information from thousands of cancer patients to enable research. It also features bioinformatic and AI tools for data analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.